Literature DB >> 111880

Detection of immune complexes by a new assay, the polyethylene glycol precipitation-complement consumption test (PEG-CC).

G D Harkiss, D L Brown.   

Abstract

A new assay for the detection of circulating immune complexes, the polyethylene glycol precipitation-complement consumption assay (PEG-CC), is described. The test is both simple and sensitive, and exhibits a high degree of specificity. Immune complexes are first isolated from serum by precipitation in 2.5% polyethylene glycol (PEG) and concentrated. They are then assayed functionally by measuring their ability to fix complement using a sensitive kinetic assay for total haemolytic complement. The test can detect aggregated IgG in serum at concentrations around 6.0 micrograms/ml (about 2.0 micrograms absolute. Using DNA-anti-DNA and ovalbumin-anti-ovalbumin immune complexes prepared in vitro, antigen concentrations less than 0.5 micrograms/ml can be detected. Interference by endogenous complement, polyanions and other factors in test sera has been virtually eliminted by the design of the assay. The increased specificity of the PEG-CC test for immune complexes, should prove useful in the diagnosis and monitoring of immune complex-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111880      PMCID: PMC1537710     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Solid-phase enzyme immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: conglutinin-binding test. A comparative study with 125I-labelled Clq binding and Raji-cell RIA tests.

Authors:  P Casali; A Bossus; N A Carpentier; P H Lambert
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

2.  Detection and radioassay of soluble circulating immune complexes using guinea pig peritoneal exudate cells.

Authors:  I I Onyewotu; E J Holborow; G D Johnson
Journal:  Nature       Date:  1974-03-08       Impact factor: 49.962

3.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

4.  Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.

Authors:  P Davis; R H Cumming; J Verrier-Jones
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

5.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

6.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

7.  Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.

Authors:  A Gabriel; V Agnello
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

8.  Detection of circulating immune complexes in patients with glomerulonephritis.

Authors:  A J Woodroffe; W A Border; A N Theofilopoulos; O Götze; R J Glassock; F J Dixon; C B Wilson
Journal:  Kidney Int       Date:  1977-10       Impact factor: 10.612

9.  C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum.

Authors:  A T Sobel; V A Bokisch; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

10.  Binding of soluble immune complexes to human lymphoblastoid cells. II. Use of Raji cells to detect circulating immune complexes in animal and human sera.

Authors:  A N Theofilopoulos; C B Wilson; V A Bokisch; F J Dixon
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

View more
  24 in total

1.  Isolation and analysis of immune complexes from sera of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  A J Smith; V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

2.  Clinicopathological study of migratory lung infiltrates.

Authors:  Y Miyagawa; N Nagata; N Shigematsu
Journal:  Thorax       Date:  1991-04       Impact factor: 9.139

Review 3.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

4.  Immune complexes in retinitis pigmentosa.

Authors:  C D Heredia; J Huguet; N Cols; P Engel; P A García-Calderón
Journal:  Br J Ophthalmol       Date:  1984-11       Impact factor: 4.638

5.  Serial analysis of circulating immune complexes, complement, and antithymocyte globulin antibodies in heart transplant recipients.

Authors:  G D Harkiss; D L Brown; R Cory-Pearce; T A English
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

6.  Hypothyroidism associated with mixed connective tissue disease and its response to steroid therapy.

Authors:  R H Withrington; M H Seifert
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

7.  Circulating immune complexes in polymyalgia rheumatica and giant cell arteritis.

Authors:  J R Park; J G Jones; G D Harkiss; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

8.  Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.

Authors:  C J Elson; S D Carter; B J Cottrell; D G Scott; P A Bacon; T B Wallington
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

9.  Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases.

Authors:  H Van Dijk; J Van Voorst; I G Jankowski; J W Imhof; J A Kerckhaert
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

10.  Continuous production of anti-host IgG antibodies contained in circulating IgG-anti-IgG complexes.

Authors:  S A Grace; C J Elson
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.